Fatty liver medical therapy: Difference between revisions
No edit summary |
No edit summary |
||
| Line 5: | Line 5: | ||
Please help WikiDoc by adding more content here. It's easy! Click [[Help:How_to_Edit_a_Page|here]] to learn about editing. | Please help WikiDoc by adding more content here. It's easy! Click [[Help:How_to_Edit_a_Page|here]] to learn about editing. | ||
== | ==Overview== | ||
The treatment of fatty liver depends on what is causing it, and generally, treating the underlying cause will reverse the process of steatosis if implemented at early stage. Recent studies suggest that [[diet (nutrition)|diet]], [[exercise]], and especially [[anti-diabetic drug|antiglycemic drug]]s may alter the course of the disease. A [[randomized controlled trial]] found that "[[pioglitazone]] led to metabolic and histologic improvement in subjects with nonalcoholic steatohepatitis".<ref name="pmid17135584">{{cite journal |author=Belfort R, Harrison SA, Brown K, ''et al'' |title=A placebo-controlled trial of pioglitazone in subjects with nonalcoholic steatohepatitis |journal=N. Engl. J. Med. |volume=355 |issue=22 |pages=2297–307 |year=2006 |pmid=17135584 |doi=10.1056/NEJMoa060326}}</ref> | The treatment of fatty liver depends on what is causing it, and generally, treating the underlying cause will reverse the process of steatosis if implemented at early stage. Recent studies suggest that [[diet (nutrition)|diet]], [[exercise]], and especially [[anti-diabetic drug|antiglycemic drug]]s may alter the course of the disease. A [[randomized controlled trial]] found that "[[pioglitazone]] led to metabolic and histologic improvement in subjects with nonalcoholic steatohepatitis".<ref name="pmid17135584">{{cite journal |author=Belfort R, Harrison SA, Brown K, ''et al'' |title=A placebo-controlled trial of pioglitazone in subjects with nonalcoholic steatohepatitis |journal=N. Engl. J. Med. |volume=355 |issue=22 |pages=2297–307 |year=2006 |pmid=17135584 |doi=10.1056/NEJMoa060326}}</ref> | ||
| Line 12: | Line 12: | ||
{{Reflist|2}} | {{Reflist|2}} | ||
[[Category:Needs content]] | [[Category:Needs content]] | ||
[[Category:Hepatology]] | |||
[[Category:Medical conditions related to obesity]] | |||
[[Category:Gastroenterology]] | |||
[[Category:Disease]] | [[Category:Disease]] | ||
Revision as of 19:34, 5 March 2013
|
Fatty Liver Microchapters |
|
Diagnosis |
|---|
|
Treatment |
|
Case Studies |
|
Fatty liver medical therapy On the Web |
|
American Roentgen Ray Society Images of Fatty liver medical therapy |
|
Risk calculators and risk factors for Fatty liver medical therapy |
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]
Please help WikiDoc by adding more content here. It's easy! Click here to learn about editing.
Overview
The treatment of fatty liver depends on what is causing it, and generally, treating the underlying cause will reverse the process of steatosis if implemented at early stage. Recent studies suggest that diet, exercise, and especially antiglycemic drugs may alter the course of the disease. A randomized controlled trial found that "pioglitazone led to metabolic and histologic improvement in subjects with nonalcoholic steatohepatitis".[1]
References
- ↑ Belfort R, Harrison SA, Brown K; et al. (2006). "A placebo-controlled trial of pioglitazone in subjects with nonalcoholic steatohepatitis". N. Engl. J. Med. 355 (22): 2297–307. doi:10.1056/NEJMoa060326. PMID 17135584.